Eagle Pharmaceuticals Inc

NASDAQ:EGRX   4:00:00 PM EDT
36.32
+1.07 (+3.04%)
4:09:32 PM EDT: $36.32 0.00 (0.00%)
Products

Eagle Pharmaceuticals Announces FDA Acceptance Of Investigational New Drug For The Treatment Of Pneumonia

Published: 11/14/2022 12:06 GMT
Eagle Pharmaceuticals Inc (EGRX) - Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for Cal02, a Novel First-in-class Broad-spectrum Anti-virulence Agent for the Adjunct Treatment of Severe Community-acquired Bacterial Pneumonia.
Eagle Pharmaceuticals Inc - Patient Enrollment Expected to Commence As Early As Beginning of 2023.
Eagle Pharmaceuticals - Expect to Begin a Phase 2 Study in About 276 Patients With Severe Community-acquired Pneumonia at About 120 Sites Worldwide.
Eagle Pharmaceuticals Inc - Cal02 is Being Developed As an Adjunct to Clinically Indicated Antibiotic Treatment.